PFIZER INC - Patent Decision.

PR Newswire UK Disclose, November, 2005

 
     U.S. Patent Office To Issue Decision Confirming Validity of Pfizer's 
                        Crystalline Patent For Lipitor 
 
    NEW YORK, Nov. 29 -- Pfizer Inc said today that the U.S. Patent and 
Trademark Office (USPTO) has announced that it will confirm the validity of 
Pfizer's U.S. patent covering the crystalline form of atorvastatin calcium used 
as the active ingredient in the cholesterol-lowering medicine Lipitor. 
    The patent office undertook a review of the patent in response to a legal 
challenge to the crystalline form patent for atorvastatin which expires in 
2017. In its response to the patent office, Pfizer argued that the unique 
crystalline form of atorvastatin calcium used in Lipitor had not been 
described in the prior art before the submission of...

            
        
    
    	    
                
                
	

		

					 
            Read the rest of this article with a Free Trial at HighBeam Research.
        				
 

    		            
	
                Premium Content Partnership | 
                	HighBeam Research provides an in-depth online archive library of reference works.